Somatic mutation profiling in -negative breast and ovarian cancer patients by multigene panel sequencing.

Targeted therapeutic agents such as poly (ADP-ribose) polymerases (PARP) inhibitors have emerged in treating cancers associated with germline mutations. Recently studies demonstrated the effectiveness of PARP inhibitors in treating patients with somatic mutations. Somatic mutations in 122 Chinese breast or ovarian cancer patients without mutations were screened using multigene sequencing panel.